Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRB | P24530 | 16/20 | 0.52 |
| ▸ | EDNRA | P25101 | 16/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7825117 | 1.00 | EDNRB (0.52) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL14298973 | 0.87 | EDNRB (0.46) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL14298965 | 0.87 | EDNRB (0.46) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL12095218 | 0.85 | EDNRB (0.45) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL7808396 | 0.85 | EDNRB (0.45) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL7814761 | 0.84 | EDNRB (0.49) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL9083425 | 0.84 | EDNRB (0.45) | EDNRBEDNRALMNATDP1KDM4E | |
| SCHEMBL9372620 | 0.83 | EDNRB (0.50) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL9084366 | 0.83 | EDNRB (0.44) | EDNRBEDNRALMNATDP1 | |
| SCHEMBL14325404 | 0.83 | EDNRB (0.55) | EDNRBEDNRALMNATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573907-B2 | 2, 4-pyrimidine derivatives and use thereof | SNU R&DB FOUNDATION (KR) | 2017-02-21 | — | — | US | disclosed |
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322802-A1 | NOVEL 2, 4-PYRIMIDINE DERIVATIVES AND USE THEREOF | LY96, AIMP1, NLRP1 | EDNRB 4586/4885EDNRA 4633/4885LMNA 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.